Artificial Intelligence in Epidemiology

Global Artificial Intelligence in Epidemiology Market to Reach US$2.6 Billion by 2030

The global market for Artificial Intelligence in Epidemiology estimated at US$685.6 Million in the year 2024, is expected to reach US$2.6 Billion by 2030, growing at a CAGR of 25.2% over the analysis period 2024-2030. Cloud-based Deployment, one of the segments analyzed in the report, is expected to record a 24.7% CAGR and reach US$2.1 Billion by the end of the analysis period. Growth in the Web-based Deployment segment is estimated at 27.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$180.2 Million While China is Forecast to Grow at 23.9% CAGR

The Artificial Intelligence in Epidemiology market in the U.S. is estimated at US$180.2 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$401.3 Million by the year 2030 trailing a CAGR of 23.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 22.9% and 21.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 17.4% CAGR.

Global Artificial Intelligence in Epidemiology Market - Key Trends & Drivers Summarized

How Is AI Transforming Epidemiology and Public Health?

Artificial Intelligence (AI) is revolutionizing the field of epidemiology by enhancing the ability to predict, detect, and manage disease outbreaks. Traditional epidemiological methods, while effective, often struggle to process large volumes of data quickly enough to respond to rapidly evolving health crises. AI addresses this challenge by using advanced machine learning algorithms, natural language processing (NLP), and predictive analytics to analyze vast datasets in real time.

AI systems monitor diverse data sources, such as electronic health records (EHRs), social media, and environmental data, to identify early signs of disease outbreaks. These tools detect patterns and anomalies that may indicate emerging health threats, enabling faster interventions. During the COVID-19 pandemic, AI played a critical role in tracking virus transmission, modeling infection trends, and supporting vaccine development efforts.

Beyond outbreak detection, AI is transforming disease modeling by simulating the impact of various interventions on public health outcomes. These simulations help policymakers design effective strategies for managing epidemics, allocating resources, and minimizing the societal impact of diseases. By enabling data-driven decision-making, AI is fundamentally reshaping the practice of epidemiology.

What Drives the Adoption of AI in Epidemiology?

The increasing frequency and complexity of disease outbreaks are significant drivers of AI adoption in epidemiology. Globalization, urbanization, and climate change are contributing to the spread of infectious diseases, creating an urgent need for advanced tools to monitor and respond to health threats. AI-powered platforms provide real-time surveillance capabilities, ensuring that public health agencies can act swiftly to contain outbreaks.

The growing availability of big data is another critical factor. Health organizations now have access to vast amounts of data from EHRs, wearable devices, genomic studies, and social media. AI systems analyze this data to uncover trends and correlations that inform public health strategies. This capability is particularly valuable in understanding the dynamics of emerging diseases and identifying vulnerable populations.

Additionally, advancements in AI technologies, such as deep learning and data visualization, are enhancing the accessibility and usability of epidemiological insights. AI tools generate user-friendly reports and visualizations that empower decision-makers at all levels, from local health departments to international organizations like the WHO. These factors highlight the growing importance of AI in addressing the challenges of modern epidemiology.

Can AI Improve Disease Prediction and Resource Allocation?

AI is proving to be a game-changer in disease prediction and resource allocation, two critical aspects of epidemiology. Predictive analytics powered by AI models forecast disease outbreaks by analyzing historical and real-time data. These forecasts enable health authorities to anticipate the spread of diseases and implement preventive measures, such as vaccination campaigns and public awareness initiatives.

In resource allocation, AI optimizes the distribution of medical supplies, personnel, and funding based on predicted disease burdens. For example, during pandemics, AI tools identify hotspots where healthcare resources are needed most, ensuring an efficient and equitable response. This capability minimizes waste and ensures that resources are directed to areas of greatest need.

AI also enhances the precision of intervention strategies by providing insights into the effectiveness of various public health measures. By simulating different scenarios, AI helps policymakers evaluate the potential outcomes of interventions, such as travel restrictions or quarantine measures. These advancements are enabling a more proactive and targeted approach to managing public health challenges.

What’s Driving the Growth of the AI in Epidemiology Market?

The growth in the Artificial Intelligence in Epidemiology market is driven by several key factors, reflecting the increasing reliance on technology to manage public health. The rising prevalence of infectious diseases and the global need for robust surveillance systems are major growth drivers. AI-powered platforms enable real-time monitoring and analysis, providing timely insights that improve outbreak response and disease control.

Technological advancements in AI, including natural language processing and deep learning, are further expanding the capabilities of epidemiological tools. These innovations enable the analysis of complex datasets and the generation of actionable insights, driving adoption among health organizations.

Consumer behavior trends, such as increased use of wearable devices and health apps, are generating valuable real-time health data that supports AI-driven epidemiology. Additionally, government and international funding for AI-based health initiatives are boosting market growth, as public health agencies invest in advanced tools to enhance their capabilities. These factors, coupled with the continuous evolution of AI technologies, are propelling the rapid expansion of the AI in Epidemiology market, positioning it as a cornerstone of modern public health strategy.

SCOPE OF STUDY:

The report analyzes the Artificial Intelligence in Epidemiology market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Deployment (Cloud-based Deployment, Web-based Deployment); Application (Infection Prediction & Forecasting Application, Disease & Syndromic Surveillance Application); End-Use (Pharma & Biotech Companies End-Use, Research Labs End-Use, Government & State Agencies End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

• Alphabet, Inc.
• Bayer AG
• Clarivate Analytics
• Cognizant Technology Solutions Corporation
• eClinicalWorks LLC
• Epic Systems Corporation
• Intel Corporation
• Komodo Health
• Koninklijke Philips NV
• Microsoft Corporation

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.